Advanced Filters
noise

Seol, Korea, Republic of Clinical Trials

A listing of Seol, Korea, Republic of clinical trials actively recruiting patients volunteers.

Found 1,135 clinical trials
K Kwang-Ha Yoo, MD, PhD

To Evaluate the Efficacy and Safety of ALC-2203 in Patients With Acute Bronchitis

A Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter, Dose-finding, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of ALC-2203 in Patients with Acute Bronchitis

19 years of age All Phase 2

The Efficacy and Safety of Atock Dry Syrup With Acute Bronchitis Patients

Clinical Study to Evaluate the Efficacy and Safety of Atock Dry Syrup with Acute bronchial Patients

6 - 11 years of age All Phase 4
J JEAYEON PARK, MD

Comparative Analysis of Core Body Temperature Measurement

Comparison and evaluation of the correlation, accuracy, and precision between a skin-attached temperature sensor and the standard method of deep body temperature measurement, the esophageal thermometer, by measuring and assessing both temperature measurement methods.

19 - 70 years of age All Phase N/A
H Heeyoung Ju, MD, PhD

Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea

Very high-risk acute lymphoblastic leukemia

1 - 19 years of age All Phase 2
J Junpil Yun, MD

RestoratIon of Myocardial Function by PeRcutaneous cOronary interVEntion in Patients With Ischemic CardioMyoPathy

To compare the effects of physiology- and imaging-guided PCI combined with optimal medical therapy (OMT) versus OMT alone on the recovery of left ventricular systolic function in patients with ischemic cardiomyopathy and multivessel coronary artery disease.

19 years of age All Phase N/A
G Gun Min Kim

Study of DM5167 in Patients With Advanced Solid Tumors

DM5167 is a second-generation of PARP inhibitor that selectively targets the PARP-1 enzyme. This results in less haematological toxicity and a high level of safety. The aim of the study is to assess the safety and tolerability of DM5167 in patients with advanced solid tumors not respond to other treatments.

19 years of age All Phase 1
A Ah hyun Lee

SupporTive Care At Home Research for Patients with Progressive Neurologic Disease Patients (STAHR-Neuro) (HOMECARE)

To test the effects of home-based care on healthcare utilization within one Year (Hospitalization Status, Number of Hospitalizations, Unplanned Hospitalization Status, Number of Unplanned Hospitalizations, Length of Hospital Stay, Number of Emergency Room Visits, Number of Outpatient Visits) among progressive neurologic disease patients with decreased performance status. Home-based care includes …

19 years of age All Phase N/A
T Tae Jun Song, MD, PhD

Efficacy and Safety of HANAROSTEN® HOT Plumber™ With Z-EUSIT™ for Pancreatic Pseudocyst Drainage

The goal of this prospective, single-center observational study is to evaluate the safety and effectiveness of the HANAROSTEN® HOT Plumber™ with Z-EUSIT™ for draining pancreatic pseudocysts. The main questions the study aims to answer are: Does the device reduce the size of pancreatic pseudocysts by at least 50% and improve …

18 years of age All Phase N/A
S Seung Wan Ryu

Effectiveness of ERAS on Postoperative Recovery After Minimally Invasive Gastrectomy

This prospective, randomized, open-label, multicenter study is designed to evaluate the impact of an enhanced recovery after surgery (ERAS) protocol on the rate of meeting discharge criteria in patients undergoing minimally-invasive gastrectomy for gastric cancer. We hypothesize that implementation of our ERAS protocol will significantly increase the proportion of patients …

19 years of age All Phase N/A
C Clinical Research Coordinator

Fluorescence Lymph Node Mapping for Colon Cancer Surgery

Fluorescence-guided surgery using indocyanine green can visualize the complex and diverse lymph node drainage structures for each patient and help determine the extent of dissection of the D3 lymph node tailored to the patient. However, since fluorescence lymph node mapping (FLNM) is still being conducted only at some institutions for …

19 - 85 years of age All Phase 2

Simplify language using AI